MedTrace Logo

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

NCT03481283 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-01-30

No results posted yet for this study

Summary

Three pieces of information lead to the basis for this study:

1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy.
2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes.
3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin.

The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.

Conditions

Sponsors & Collaborators

  • Zabeen Mahuwala, MD

    lead OTHER

Principal Investigators

  • John T Slevin, M.D., M.B.A. · University of Kentucky Department of Neurology

  • Zabeen Mahuwala, MD · University of Kentucky

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03481283 on ClinicalTrials.gov